← back to search

Alberto Ascherio

Harvard University · US
🔎 Find collaborators in Pathology and Forensic Medicine · Neurology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Alberto Ascherio, MD, DrPH, is a Professor of Epidemiology and Nutrition at the Harvard T. H. Chan School of Public Health and a Professor of Medicine at the Harvard Medical School. Dr. Ascherio received a Doctorate in Medicine and Surgery from the University of Milan and worked for several years in medicine and public health in Latin America and Africa before obtaining a Master and Doctorate in Public Health from Harvard. Dr. Ascherio has focused much of his work over the past 25 years on discovering the causes of neurodegenerative diseases, including multiple sclerosis (MS), Parkinson disease, amyotrophic lateral sclerosis, and cognitive decline. He has conducted longitudinal studies in many populations, including, among others, the Nurses’ Health Studies I and II, the Health Professionals Follow-up Study, the Cancer Prevention Study-II, the U.S Army, Navy and Air Force, the Danish MS Registry, and the Finnish Maternal Cohort. These studies have contributed to identifying several biomarkers and modifiable risk factors for MS (e.g. cigarette smoking, vitamin D insufficiency, and childhood obesity), Parkinson (pesticide exposure, low caffeine intake, low physical activity), and ALS (cigarette smoking, military service, low body mass index), and have in some cases provided the rationale for randomized trials (e.g. on physical activity in Parkinson disease). His most notable scientific contribution stems from the 20-year long investigation of over 10 million young adults that led to the recent breakthrough discovery that MS is a rare complication of infection with the Epstein-Barr virus.
h-index
130
citations
59,388
works
406
NIH funding
primary concept
Medicine
email

Recent publications

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson’s disease
2026cited by 0position: contributordoi
Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease
Neurology 2025cited by 10position: middledoi
Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease.
2025cited by 7position: contributordoi
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
2025cited by 3position: contributordoi
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Neurology 2025cited by 3position: contributordoi
Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis
JAMA Neurology 2024cited by 31position: lastdoi
Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.
2023cited by 165position: contributordoi
Association of the Mediterranean Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet With the Risk of Dementia
JAMA Psychiatry 2023cited by 140position: middledoi
Integrating genetics and metabolomics from multi-ethnic and multi-fluid data reveals putative mechanisms for age-related macular degeneration
Cell Reports Medicine 2023cited by 40position: middledoi
Long‐Term Intake of Folate, Vitamin <scp>B6</scp>, and Vitamin <scp>B12</scp> and the Incidence of Parkinson's Disease in a Sample of <scp>U.S.</scp> Women and Men
Movement Disorders 2023cited by 22position: lastdoi
The intricate connection between diabetes mellitus and Parkinson's disease.
2023cited by 3position: contributordoi
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Science 2022cited by 1,946position: lastdoi
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
2022cited by 1,351position: contributordoi
The Potential for EBV Vaccines to Prevent Multiple Sclerosis
Frontiers in Neurology 2022cited by 44position: middledoi
Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease
JAMA Network Open 2022cited by 40position: middledoi
Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
2021cited by 10position: contributordoi
Maternal prepregnancy BMI and physical activity and type 1 diabetes in the offspring.
2021cited by 1position: contributordoi
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk
European Heart Journal 2020cited by 356position: middledoi
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
JAMA Neurology 2019cited by 260position: lastdoi
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial
Neurology 2019cited by 43position: middledoi
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update
Seminars in Neurology 2016cited by 307position: lastdoi
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b
JAMA Neurology 2015cited by 168position: lastdoi
Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study
Annals of the Rheumatic Diseases 2015cited by 146position: middledoi
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
JAMA Neurology 2014cited by 511position: firstdoi
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
JAMA Neurology 2014cited by 239position: middledoi
Mendelian randomization of serum urate and parkinson disease progression
Annals of Neurology 2014cited by 89position: middledoi
Environmental factors in multiple sclerosis
Expert Review of Neurotherapeutics 2013cited by 337position: firstdoi
Research on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
Environmental Health Perspectives 2013cited by 80position: middledoi
Habitual intake of dietary flavonoids and risk of Parkinson disease
Neurology 2012cited by 328position: lastdoi
The initiation and prevention of multiple sclerosis
Nature Reviews Neurology 2012cited by 288position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 9 papers (2021–2026)Kassandra L. Munger · Harvard University7 papers (2012–2024)Kjetil Bjornevik · Harvard University6 papers (2022–2025)Kjetil Bjørnevik · Harvard University5 papers (2019–2025)Michael A. Schwarzschild · Harvard University5 papers (2012–2023)Brian C. Healy · Harvard University4 papers (2019–2024)Caroline M. Tanner · San Francisco VA Medical Center3 papers (2012–2014)David W. Niebuhr · Uniformed Services University of the Health Sciences3 papers (2019–2024)Marianna Cortese · University of Bergen3 papers (2021–2025)Stephen J. Elledge · Harvard University3 papers (2022–2024)Marianna Cortese · Harvard University3 papers (2019–2024)Yumei Leng · Harvard University2 papers (2022–2024)Kassandra L. Munger · Biogen (United States)2 papers (2021–2022)Mario H. Flores-Torres · Harvard University2 papers (2025–2025)Albert Y. Hung · Harvard University2 papers (2019–2023)Michael J. Mina · Miami Transplant Institute2 papers (2022–2024) · 2 papers (2014–2014)Karl Köchert · Sanofi (Germany)2 papers (2014–2015)Ira Shoulson · Vitality Institute2 papers (2012–2014)Neha Khandpur · Harvard University2 papers (2025–2025)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pathology and Forensic Medicine · Neurology →